| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10059083 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10059096 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10060256 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10060257 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10057739 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10059082 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10060255 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10059077 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10059094 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
| TVIS10059080 | HBV | ENSG00000160282.15 | protein_coding | FTCD | No | No | 10841 | O95954 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FTCD |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000822 |
| UniProt ID | O95954 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 9837973 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Gao YS, Alvarez C, Nelson DS, Sztul E: Molecular cloning, characterization, and dynamics of rat formiminotransferase cyclodeaminase, a Golgi-associated 58-kDa protein. J Biol Chem. 1998 Dec 11;273(50):33825-34. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
